**Ocumension Therapeutics**
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*
**(Stock code: 1477)**

# VOLUNTARY ANNOUNCEMENT

# INITIATION OF SECOND PHASE III CLINICAL TRIAL OF OT-301 IN THE UNITED STATES

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the second phase III clinical trial of OT-301(NCX 470), namely the Denali trial, has been initiated in the United States by the Group's licensing partner and the originator of NCX470, Nicox S.A. ("**Nicox**"), with the first patients enrolled in the United States on November 9, 2020.

OT-301(NCX 470), is a first-in-class, second-generation nitric oxide (NO)-donating bimatoprost analog under development by Nicox and the Group, which is intended to lower intraocular pressure ("**IOP**") in patients with open-angle glaucoma or ocular hypertension.

The second phase III clinical trial of OT-301(NCX 470), namely the Denali trial, is a three-month phase III multi-regional clinical trial evaluating the safety and efficacy of OT-301(NCX 470) ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The Denali trial, which will also include a long-term safety extension, is expected to randomize approximately 670 patients, at approximately 50 clinical sites in the United States and the People's Republic of China (the "**PRC**" or "**China**"). The Denali trial was designed to fulfil the regulatory requirements to support new drug application submissions of OT-301(NCX 470) in the United States and China. The collaboration between Nicox and the Group on the Denali trial has allowed the trial to be initiated earlier than planned and may potentially accelerate the new drug application submissions in both the United States and China. With the initiation of the Denali trial, the joint development of OT-301(NCX 470) is entering the final phase of development and remains on track.

The first phase III clinical trial of OT-301(NCX 470), namely the ongoing Mont Blanc trial, was initiated in the United States in June 2020 and has been approved by the Center for Drug Evaluation of the National Medical Products Administration of the PRC in October 2020 to carry out part of the Mont Blanc trial in China. The top-line results of the Mont Blanc trial are currently expected in the fourth quarter of 2021.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will ultimately commercialize OT-301(NCX 470) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
**Ocumension Therapeutics**
**Dr. Lian Yong CHEN**
*Chairman and Executive Director*

Hong Kong, November 11, 2020

*As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.*